Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHPMF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.07 Med: 3.33 Max: 4.59
Current: 4.59
During the past 13 years, the highest Debt-to-EBITDA Ratio of Shanghai Pharmaceuticals Holding Co was 4.59. The lowest was 2.07. And the median was 3.33.
SHPMF's Debt-to-EBITDA is ranked worse than 74.44% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs SHPMF: 4.59
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shanghai Pharmaceuticals Holding Co Debt-to-EBITDA Related Terms
Shanghai Pharmaceuticals Holding Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co Debt-to-EBITDA Chart
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Shanghai Pharmaceuticals Holding Co (SHPMF) has a Debt-to-EBITDA of 4.84 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Pharmaceuticals Holding Co. This is 45% above median its historical median of 3.33. Over the past decade, Shanghai Pharmaceuticals Holding Co's Debt-to-EBITDA has ranged from 2.07 to 4.59. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #67 out of 90 companies in the Medical Distribution industry, placing it in the top 74.4%.
Is Shanghai Pharmaceuticals Holding Co's Debt-to-EBITDA too high?
Shanghai Pharmaceuticals Holding Co's current Debt-to-EBITDA of 4.84 is 45% above median its 10-year median of 3.33. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 4.59. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Shanghai Pharmaceuticals Holding Co's value of 4.84 is 97.6% above this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #67 out of 90 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #67 out of 90 companies for Debt-to-EBITDA. This places Shanghai Pharmaceuticals Holding Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. Shanghai Pharmaceuticals Holding Co's value of 4.84 is 97.6% above this benchmark. Historically, Shanghai Pharmaceuticals Holding Co's own Debt-to-EBITDA has ranged from 2.07 to 4.59 over the past decade. While the company's 10-year median is 3.33 vs. the industry median of 2.45, Shanghai Pharmaceuticals Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current Debt-to-EBITDA of 4.84 is 97.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Pharmaceuticals Holding Co. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current Debt-to-EBITDA is 4.84, which is 45% above median its own 10-year median of 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current Debt-to-EBITDA of 4.84. The stock's GF Value™ is $1.76, compared to a current price of $1.46 — trading 17% below its estimated fair value. The current Debt-to-EBITDA is 4.84, which is 45% above median its 10-year median of 3.33 and 97.6% above the Medical Distribution industry median of 2.45. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current Debt-to-EBITDA is 4.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $1.46 is trading 17% below its estimated GF Value™ of $1.76.
Key valuation signals for SHPMF:
Debt-to-EBITDA: 4.84 (45% above median its 10-year median of 3.33)
GF Value™: $1.76 vs. price of $1.46 (17% below fair value)
Industry Position: 97.6% above the Medical Distribution median (#67 of 90)
No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
73GF Score
Get the complete analysis for SHPMF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMF has been successfully added to your 
